Merck KGaA Builds On Diabetes Portfolio With DPP-IV Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA is looking to build on its heritage in diabetes research with the addition of a dipeptidyl peptidase IV inhibitor. The German company announced an agreement with Mumbai, India-based Glenmark to license a Phase II DPP-IV, GRC 8200, on Oct. 18